Phaseline

Targets › SYK

SYK (Tyrosine-protein kinase SYK): drug programs, companies and trials

7 programs from 7 companies in 8 trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Hematology, Oncology, Other; next expected readout Nov 2026.

Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. (UniProt, P43405)

Open in Phaseline: the race on SYK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupTQB3473
Spleen tyrosine kinase (Syk) inhibitor
SYKPhase 3Primary Immune ThrombocytopeniaMar 2027
HutchmedSovleplenib (HMPL-523)
Tyrosine-protein kinase SYK inhibitor
SYKPhase 2Warm Antibody Autoimmune Hemolytic AnemiaNov 2026
Seoul National University HospitalPoseltinib
Spleen tyrosine kinase (SYK) inhibitor
SYKPhase 2Relapsed/refractory Diffuse Large B Cell LymphomaNov 2026
National Heart, Lung, and Blood Institute (NHLBI)Fostamatinib
Tyrosine-protein kinase SYK inhibitor
SYKPhase 1Sickle Cell Disorders; Lung TransplantationMay 2027
University of California, San DiegoFostamatinib
Tyrosine-protein kinase SYK inhibitor
SYKPhase 1Pancreatic Ductal Adenocarcinoma (PDAC)Dec 2027
Stefanie Sarantopoulos, MD, PhD.Fostamatinib
Tyrosine-protein kinase SYK inhibitor
SYKPhase 1Chronic Graft Versus Host DiseaseJan 2029
Imperial College LondonFostamatinib
Tyrosine-protein kinase SYK inhibitor
SYKPhase 1Renal Transplant Rejection–

Conditions

Primary Immune Thrombocytopenia (1) Sickle Cell Disorders (1) Lung Transplantation (1) Chronic Graft Versus Host Disease (1) Warm Antibody Autoimmune Hemolytic Anemia (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Renal Transplant Rejection (1) Relapsed/refractory Diffuse Large B Cell Lymphoma (1)

Modalities

small molecule (4), protein or peptide (1), antibody (1)

Companies

Chia Tai Tianqing Pharmaceutical Group (1) National Heart, Lung, and Blood Institute (NHLBI) (1) Stefanie Sarantopoulos, MD, PhD. (1) Hutchmed (1) University of California, San Diego (1) Imperial College London (1) Seoul National University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.